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EBV-associated diseases in humans
Epstein-Barr virus (EBV) is one of eight known 
human herpesviruses (HHVs) and a member of the 
gamma herpesvirus family (lymphocryptovirus). 
EBV was the first human tumor virus identified 
from cultured lymphoblasts of Burkitt sʼ lymphoma 
(Epstein et al., 1964), and its potential role as a 
causative agent of EBV-associated tumors has been 
EBV-Associated Diseases in Humans and their Animal 
in vivo Models:  Part I
Kazuhiko Hayashi
Division of Molecular Pathology, Department of Microbiology and Pathology, School of 
Medicine, Tottori University Faculty of Medicine, Yonago 683-8503 Japan 
Epstein-Barr virus (EBV) is one of human herpesviruses and a member of the gamma 
herpesvirus family (lymphocryptovirus).  Infectious mononucleosis, Burkittʼs lymphoma 
and nasopharyngeal carcinoma are well-known EBV-associated diseases.  The range of 
EBV-associated diseases has recently expanded to include Hodgkinʼs lymphoma, T-cell 
lymphoma, pyothorax-associated or methotrexate-associated B-cell lymphoma, primary 
effusion lymphoma and lymphoepithelioma-like carcinoma of the stomach, thymus and 
salivary gland, lymphoproliferative disorders (LPDs) or leiomyosarcomas from im-
munocompromized host, oral hairy leukoplakia and EBV-associated hemophagocytic 
syndrome.  Animal models of human EBV-associated diseases are essential to elucidate 
the pathogenesis of EBV-infection and EBV-associated diseases.  However, only several 
reports on the animal models of EBV infection have been reported.  Here I review the 
summary of EBV-associated diseases in humans and those previous animal models using 
EBV or EBV-like herpesviruses and describe some details on our two newly developed 
rabbit models of LPD induced by simian EBV-like viruses and a mouse model with mu-
rine gammaherpesvirus.  These animal models are useful and inexpensive alternative 
experimental model systems for studying the biology and pathogenesis of EBV, and pro-
phylactic and therapeutic regimens.
Key words:  animal model; EBV-associated disease; human; lymphocryptovirus
the important subject of such investigation for the 
last 40 years.  EBV preferentially infects human 
B cells, T cells, natural killer (NK) cells, epithe-
lial cells and smooth muscle cells (Rickinson and 
Kieff, 2001).  Latent EBV infection occurs in the 
oropharyngeal epithelium, where EBV virions are 
replicated and released from the epithelial cells to 
saliva.  The EBV-infected cells express a differ-
ent array of EBV-associated antigens depending 
on lytic or latent infection (Baer et al., 1984; Rowe 
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et al., 1992), and these viral antigens are targeted 
by EBV-specific cytotoxic T lymphocytes (CTLs) 
(Catalina et al., 2001).  The CTL responses to 
EBV infections induce a variety of inflammatory 
systemic symptoms.  On the other hand, the lack 
of CTLs such as in patients with congenital immu-
nodeficiencies or acquired immunodeficiency syn-
drome (AIDS) or in recipients receiving a potent 
immunosuppressant, allows EBV-infected cells to 
proliferate and result in the development of lethal 
lymphoproliferative diseases (LPDs).  EBV is clas-
sically associated with infectious mononucleosis 
(IM), Burkitt sʼ lymphoma in equatorial Africa and 
nasopharyngeal carcinoma (Rickinson and Kieff, 
2001).  The range of EBV-associated diseases has 
recently expanded to include oral hairy leukoplakia, 
leiomyosarcoma from AIDS patients, Hodgkin sʼ 
lymphoma, T-cell lymphoma, Ki-1 lymphoma, 
pyothorax-associated B-cell lymphoma, methotrex-
ate-associated B-cell lymphoma, primary effusion 
lymphoma, LPDs of primary and secondary im-
munodeficiency, and lymphoepithelioma-like car-
cinoma of the stomach, thymus, lung and salivary 
gland (Weiss et al., 1989; Chang et al., 1992; Weiss 
and Chang, 1996; Anagnostopoulos and Hummel, 
1996; Kawa, 2000; Iwatuski et al., 2004) (Table 1, 
Fig. 1). 
Primary EBV infection and its associated 
diseases
Infectious mononucleosis
Acute IM is clinically characterized by fever, 
lymphadenopathy, tonsillitis, pharyngolaryngitits 
and hepatosplenomegaly, and increased IgM and 
IgG antibodies to EBV-viral capsid antigens (VCAs) 
and early antigens (EAs).  Acute IM is fairly com-
mon in the United States and Western Europe, 
where a primary infection often occurs during 
adolescence.  Asymptomatic primary infections are 
common in Asia and developing countries because 
primary EBV infections occur early in life.  EBV 
virions bearing gp350/220 infect B cells via CD21 
(CR2) or a receptor for C3d, and form an episomal 
EBV in the nucleus (Fingeroth et al., 1984).  A 
complex of gp85(gH)/gp25(gL)/gp42 binds to HLA 
class II molecules to induce cell membrane fusion 
in B cells (Molesworth et al., 2000).  Binding of 
the gp42 molecule to HLA class II is essential for 
virus entry into B cells.  Following an incubation pe-
riod of 2 to 7 weeks, EBV-infected B cells increase 
in number during acute IM.  The EBV-infected B 
cells, however, are quickly abrogated by cellular 
immune responses mediated by NK cells, activated 
T cells and antibody-dependent cell-mediated cyto-
toxicity (Rickinson and Moss, 1997).  CD8+, HLA-
DR+ activated T cells increase in peripheral blood, 
and are defined as “mononucleosis” by hemograms 
when systemic symptoms manifest. During IM as 
primary EBV infection, EBV is capable of express-
ing all viral antigens of lytic cycle: immediate 
early, early and late proteins, and all antigens of la-
tent infection genes:  six EBV-determined nuclear 
antigens (EBNAs) consisting of EBNA-1, -2, -3A, 
-3B, -3C and -leader protein (LP), and three latent 
membrane proteins (LMPs), including LMP-1, -2A 
and -2B (latency type III, Table 1).  All viral anti-
gens of lytic cycle, all EBNAs and LMPs, except 
for EBNA-1, are target molecules for EBV-specific 
cytotoxic T cells.  Therefore, CTLs direted to these 
EBV antigens suppress the EBV-infected cells in 
immunocompetent hosts.
EBV-associated hemophagocytic syndrome
Hemophagocytic syndrome is an unusual syndrome 
characterized by fever, splenomegaly, jaundice, 
pancytopenia, disseminated intravascular coagula-
tion, and features of increased hemophagocytic 
macrophages in the bone marrow and other tissues 
(Imashuku, 2002).  EBV-associated hemophago-
cytic syndrome (EBV-AHS) may be associated 
with acute IM, and EBV-associated LPD, lympho-
mas, cancers and autoimmune diseases, and com-
monly occurs in children and adolescents in Asia, 
but is rarely seen in Western countries.  Laboratory 
examinations reveal pancytopenia, liver dysfunc-
tion, coagulopathy, elevated levels of lactate dehy-
drogenase, ferritin, β2-microglobulin, and serum 
cytokines including IFN-γ, IL-6, IL-10, sIL-2R, 
sFas and Fas L (Imashuku, 2002).  These cytokines 
increased in the process of CTL responses directed 
against EBV-infected CD8+ T cells may induce he-
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Table 1.  Comparative overview of EBV-associated diseases (tumors) in humans and their compat-
ible animal models
   Type of   EBV-associated  Proposed  EBV latent  Latency  Animal 
 infection or diseases cell gene expression type model
   disease   of origin
Primary  IM B cell EBNA-1+, -2+, -3A+,  III  + 
  infection   -3B+, -3C+, -LP+,  (with (monkey, 
   LMP-1+, -2+ lytic cells) mice)
Primary  EBV-AHS/fatal IM  T cell  EBNA-1+, (LMP-1+), I/II +
  infection (T-LPD)  LMP-2+   (rabbit)
Chronic  X-linked LPD B cell EBNA-1+, -2+, -3A+,  III   –
  infection/     -3B+, -3C+, -LP+,  (with
  LPD   LMP-1+, -2+ lytic cells) 
Chronic  PTLD-like lymphoma  B lympho- EBNA-1+, -2+, -3A+,  III  + 
  infection/ (B-LPD) from immuno- blast -3B+, -3C+, -LP+,  (with  (monkey, 
  LPD compromised host  LMP-1+, -2+ lytic mice, 
 (congenital immunodeficiency,   cells) scid mice)
 transplantation, AIDS)    
Chronic Chronic active EBV  T cell or  EBNA-1+, LMP-1+, -2+ II –
  infection/ infection NK cell 
  LPD   
Lymphoma Burkitt sʼ lymphoma B cell  EBNA-1+ I –
  (centroblast) 
Lymphoma Pyothorax-associated  B cell EBNA-2+, LMP-1+ III –
 lymphoma
Lymphoma  Primary effusion  B cell EBNA-1+, (LMP-1+),  I/II –
  (co-infection lymphoma  
  with HHV-8)
Lymphoma Methotraxate-associated  B cell (LMP-1+) I/II ? –
 lymphoma (LPD)
Lymphoma Hodgkin sʼ lymphoma B cell  EBNA-1+, LMP-1+, -2+ II –
  (centrocyte)   
Lymphoma/ T-cell lymphoma T cell  EBNA-1+, (LMP-1+),   I/II  + 
  leukemia   LMP-2+  (rabbit)
Lymphoma/ Nasal T/NK cell  T/NK cell EBNA-1+, (LMP-1+),  I/II –
  leukemia lymphoma  LMP-2+  
Carcinoma Gastric carcinoma Epithelial  EBNA-1+, LMP-2+ I/II –
  cell
Carcinoma Nasopharyngeal  Squamous  EBNA-1+, (LMP-1+),   I/II –
 carcinoma cell LMP-2+ 
Virus replica- Oral hairy leukoplakia Squamous  EBNA-1+, -2+, -3A+,  III   +
  tive lesion  cell -3B+, -3C+, -LP+,  (with  (monkey)
   LMP-1+, -2+ lytic cells) 
Sarcoma Leiomyosarcoma from  Smooth   EBNA-1+, -2+, -3A+,  III  –
 immunocompromised  muscle -3B+, -3C+, -LP+, 
 host  LMP-1+, -2+
This table was modified from the tables in the textbook (Rickinson and Kieff, 2001).  
EBV, Epstein-Barr virus; EBV-AHS, EBV-sassociated hemophagocytic syndrome; HHV-8, human herpesvirus-8; 
IM, infectious mononucleosis;  LPD, lymphoproliferative disease; PTLD, post-transplant lymphoproliferative dis-
ease.
mophagocytosis by activated macrophages.  Latent 
EBV infection is also detected in other lymphocyte 
subsets of CD4+ T cells, CD16+ NK cells and 
CD20+ B cells (Kasahara et al., 2001).
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against EBV antigens, which may allow the survival 
of EBV-infected NK or T cells.
EBV latent infection and tumor development 
Most EBV-associated LPDs are of B cell lineage, 
but T cell neoplasms and Hodgkinʼs lymphoma 
may occur.  Latent EBV infection plays a pivotal 
role in the occurrence of African Burkitt sʼ lym-
phoma, pyothorax-associated lymphomas (PALs), 
Hodgkin sʼ lymphoma (Figs. 1a and b), primary ef-
fusion lymphoma induced by HHV-8 coinfection, 
and various types of B cell lymphomas (Iwatsuki et 
al., 2004).  The association of latent EBV infection 
with NK/T cell lymphomas is less common than B 
cell lymphomas.  Extranodal NK/T-cell lymphoma, 
nasal type is more prevalent in Asia, Mexico and 
Central and South America, and a disease char-
acterized by histological features of angiocentric 
and angiodestructive infiltration of lymphoma cells 
with severe ulceration or necrosis in nasal cavity. 
All those LPD except PAL have latency type I or II, 
whereas latency type III is detected in PAL.  PAL 
is considered to have a localized immunodeficiency 
in pyothorax lesions.
        EBV-associated carcinomas such as nasopha-
ryngeal carcinoma and stomach carcinoma (Figs. 
1c and d) show latency type I/II.  Entry of EBV 
into epithelial cells that do not express CD21 or 
HLA class II is mediated by gp85(gH)/gp25(gL) 
complexes without gp42 (Borza and Hutt-Fletcher, 
2002).  The restriction of EBV gene expression 
such as latency type I (or II) showing only EBNA-1 
(or LMPs) allows EBV-infected cells to evade im-
mune surveillance, and persists throughout latent 
infection.  EBNA-1 is essential for replicating EBV 
episomes during latency by binding to OriP, a cis-
acting element of the EBV genome, and by promot-
ing the replication of viral episomes by host cell 
DNA polymerase.  LMP-1 shows oncogene activity 
with the upregulation of cellular gene expression in 
various cell types, and prevents apoptosis by the 
induction of bcl-2 (Rickinson and Kieff, 2001). 
        EBV-AHS, CAEBV and NK/T cell lympho-
mas are common in Asia (Iwatsuki et al., 2004). 
Since EBV gene expression is restricted in these 
disorders (latency II), only LMPs expressed by 
EBV-associated LPD or leiomyosarcomas 
in immunocompromized indivisuals
In patients with congenital immunodeficiencies 
or AIDS or in recipients of organ transplantaions 
receiving a potent immunosuppressant, the lack or 
suppression of CTLs caused the EBV-associated 
B-cell LPD with latency type III infection of EBV. 
EBV is also involved in patients with methotrexate-
associated LPD.  Leiomyosarcomas may also de-
velop in the immunocompromized hosts, although 
mechanism of EBV infection to smooth muscles 
has not been clarified (Rickinson and Kieff, 2001).
Chronic and latent EBV infection and their 
associated diseases 
X-linked lymphoproliferative syndrome (Duncan 
disease)
In patients with X-linked lymphoproliferative syn-
drome, an inherited immunodeficiency character-
ized by increased susceptibility to EBV and B-cell 
LPD (Nichols et al., 1998), the presence of small 
deletions and mutations in DSHP/SH2DIA/SLAM-
associated protein (SAP) gene was detected. 
Chronic active EBV infection
Chronic active EBV infection (CAEBV) is a dis-
ease of CD4+ T-cell or NK cell LPD characterized 
by chronic or recurrent infectious mononucleosis–
like symptoms persisting over a long time and by 
abnormally high titers of anti-EBV antibodies and 
increased levels of EBV-DNA in the peripheral 
blood (Okano, 1991).  CAEBV is also characterized 
by a high mortality and high morbidity with life-
threatening complications, such as virus-associated 
hemophagocytic synrome, interstitial pneumonia 
and malignant lymphomas several years after dis-
ease onset.  Patients with T-cell CAEBV had a 
shorter survival time than those with NK-cell type 
of disease (Kimura et al., 2001).  Latency type II in-
fection of EBV expressing EBNA-1 and LMPs pro-
teins is demonstrated in cases with CAEBV.  How-
ever, patients with CAEBV may have congenital or 
acquired immunological defects in CTL responses 
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Fig. 1.  Representative EBV-associated tumors in humans.  
 a: Hodgkin sʼ lymphoma, hematoxylin and eosin stain.  
 b: EBER-1+ Hodgkin and Reed-Sternberg cells observed in Hodgkin sʼ lymphoma.  EBV-EBER-1 ISH.  
 c: Gastric adenocarcinoma, hematoxylin and eosin stain.    
 d: EBER-1 expression in adenocarcinoma of stomach.  EBV-EBER-1 ISH. 
the EBV-infected cells are targeted by host CTLs. 
Despite the absence of overt immunodefi ciency, 
EBV-infected cells are insuffi ciently abrogated by 
CTLs in these disorders.  Therefore, selective im-
munological defects to LMPs as genetic predisposi-
tion can be considered in those patients, including 
an HLA-restricted low response of CTLs to LMPs, 
immunological tolerance to LMPs and selective de-
letion of LMP-specifi c CTLs.
        The release of virokines such as vIL-10 and 
the down-regulation of cell adhesion molecules are 
additional strategies for EBV-infected cells with 
latency type I/II to evade the host immune system. 
vIL-10 inhibits the synthesis of IFN-γ from lympho-
cytes and NK cells, and suppresses IFN-γ-mediated 
cellular events such as the up-regulation of the MHC 
class I expression and CTL responses.  Low levels 
of intercellular adhesion molecule 1 and leukocyte 
function-associated antigen 3 expression are as-
sociated with an impaired ability to interact with 
EBV-specifi c CTL (Iwatsuki et al., 2004).
        Most EBV-associated tumors arise with a very 
long latency in long-term EBV carriers.  This sug-
gests the multistep oncogenesis through malignant 
transformation from a single cell within the EBV-
infected pool (Rickinson and Kieff, 2001).  EBV 
may require certain risk factors to induce malig-
nancy in humans.  These risk factors are immuno-
logic risk factor, genetic risk factors such as racial 
predisposition and personal predisposition, and 
environmental risk factors like Euphorbia tirucalli 
and malarial infection for African Burkitt sʼ lym-
phoma (Osato, 1998).  The translocation of c-myc 





like p53 are needed for the development of the most 
EBV-associated tumors in addition to EBV infec-
tion.
        Despite intensive investigations on the role 
of EBV infection in the pathogenesis of EBV-
associated tumors, a causal relationship between 
EBV and these tumors has not been established 
except for LPD arising in immunosuppressed indi-
viduals.  Therefore, animal models of human EBV-
associated diseases are essential to elucidate the 
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